Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xenon and Cooling Therapy in Newborns with HIE
NCT02071394Phase 2Completed
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Mar 2014
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of xenon in hypoxic-ischemic encephalopathy (HIE) (2 arms), sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoint: Death and moderate or severe disability - Bayley III neurodevelopmental outcome score at 18 months. Started Mar 2014; status: completed.
02
Drugs
xenon
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT02071394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071394.